No Evidence Supporting Beet Juice for COPD Relief in Clinical Guidelines
There is no guideline-level evidence supporting the use of beet juice (beetroot juice) for COPD management, and it should not be recommended as a treatment for relieving COPD symptoms. The established COPD guidelines from major respiratory societies make no mention of dietary nitrate supplementation or beet juice as part of standard care 1, 2, 1.
What the Guidelines Actually Recommend
The evidence-based treatments for COPD that improve morbidity, mortality, and quality of life include:
- Smoking cessation - the single most important intervention affecting outcomes 3, 4
- Bronchodilators (β2-agonists, anticholinergics, LABAs, LAMAs) - central to symptom management 1, 3, 1
- Inhaled corticosteroids combined with LABAs for patients with exacerbations and moderate-to-severe disease 1
- Pulmonary rehabilitation - improves exercise performance and reduces breathlessness 2, 4
- Supplemental oxygen - reduces mortality in patients with resting hypoxia (PaO2 <7.3 kPa) 2, 4
The Research Evidence on Beet Juice
While recent research studies have examined beet juice supplementation in COPD, the findings are inconsistent and do not rise to the level of guideline recommendations:
Modest exercise improvements in some studies:
- A 2026 meta-analysis found beet juice improved exercise capacity (SMD 0.31), with greater benefits in parallel trials (SMD 0.52) than crossover trials (SMD 0.06) 5
- One 2015 study showed increased exercise time (375 vs 346 seconds) and reduced blood pressure 6
- A 2024 meta-analysis suggested dietary nitrate may increase exercise capacity 7
Negative or neutral findings:
- A 2017 trial using higher doses for longer duration found NO improvement in 6-minute walk distance, oxygen consumption, or physical activity level, though diastolic blood pressure decreased 8
- The effects appear limited to exercise capacity metrics rather than clinically meaningful outcomes like exacerbations, hospitalizations, or mortality
Critical Limitations
Why this doesn't translate to clinical recommendations:
- No impact on mortality or exacerbations - the outcomes that matter most for COPD patients
- Inconsistent results across studies, with study design significantly affecting outcomes
- Small effect sizes - even when positive, improvements are modest
- Short-term studies only - no long-term safety or efficacy data
- Not included in any major guideline (GOLD, BTS, ERS) despite years of research
Clinical Bottom Line
Focus on proven therapies first: Ensure your patient is on appropriate bronchodilators, has stopped smoking, and qualifies for pulmonary rehabilitation or oxygen therapy if indicated 1, 2, 1. These interventions have robust evidence for improving mortality, reducing exacerbations, and enhancing quality of life.
If a patient asks about beet juice, you can acknowledge that some research shows minor improvements in exercise testing, but emphasize this is not a substitute for evidence-based COPD management. The modest exercise capacity improvements seen in research studies do not translate to the meaningful clinical outcomes (reduced hospitalizations, fewer exacerbations, improved survival) that established COPD therapies provide.
Common pitfall: Patients may pursue unproven supplements while neglecting proven interventions like smoking cessation, proper inhaler technique, or pulmonary rehabilitation. Always redirect focus to guideline-concordant care that actually impacts morbidity and mortality.